

# 온라인 세미나 사전 접수 안내

Time	Topics
Time	Торкс
13:00~13:10	Opening
13:10~13:50	Antibody-drug conjugates(ADCs): current progress and selection of preclinical animal models –Shuang Li, PhD
13:50~14:30	CD3EDG humanized mice: a powerful tool for advancing CD3 bispecifics preclinical evaluation-Shuang Li, PhD
14:30~15:00	The applications of physiologicla/phathological organoid models and organoid chips - Ding Duanchen , PhD
15:00~15:05	Quiz
15:05~15:20	BREAK TIME
15:20~15:50	ICH M10 Bioanalytical Method Validation and Sample Analysis by Ligand Binding and Chromatographic Assays-Huafang Jiang, PhD
15:50~16:15	Non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals-Qi Huang, PhD
16:15~16:20	Unexpected Quiz
16:20~16:55	초기신약 발굴 및 개발에서의 in vitro assay, in vivo PK-남원석 Ph.D
16:55~17:05	Q&A
17:05~17:10	Last Quize
17:10~	END

대 상 자: 제약업체 연구원 및 관련기관 종사자

인 원: 선착순 250명 종료 시 마감

시: 2024년 09월 06일(금) 13:30~

소: Zoom Webinar Online 개최

신청기간: 2024년 08월 21일(수) ~ 2024년 09월 04일(수)

등 록 비: 무료

신청방법: 링크 접속 후 신청서 작성: https://forms.gle/pZ9FQY4MgNT89nJy5

신청완료 후 한국비임상기술지원센터에서 신청확인 메일 발송 예정(<mark>영업일 기준 3일 이내),</mark> 확인 메일 받은 <mark>신청자에 한하여 온라인 세미나</mark> 참석가능

문 의 처: Tel. 031-759-9934 / E-mail. <u>overseas@kntsc.kr</u> 담당자 : 김은향 ✓ 교육 세션은 원활한 진행을 위해 레코딩으로 진행됩니다

- ✓ 해외연자 강연은 영어로 진행되며, 한국어 자막이 제공됩니다
- ✓ Q/A 세션은 LIVE로 진행됩니다.
- ✓ Q/A 세션은 국내강연에서만 진행됩니다 ✓ 온라인 세미나 진행중 이벤트가 있을 예정입니다.





Shuang Li, PhD

#### CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS

Shuang Li received his Bachelor's degree from the School of Life Sciences, Jilin University, Master's degree from Peking University, and PhD degree from the Free University of Brussels, Belgium, majori ng in Medical Immunology. He has worked in Hengrui and other well-known pharmaceutical compani es in the early development of oncology and immunology drugs and pharmacological and pharmacod ynamic studies.

Currently, he is mainly engaged in the development and validation of humanised animal models and in vivo pharmacological and pharmacodynamic studies in mice at SMOC. She has published research papers in PNAS and other international journals, and specialises in the fields of tumour immunity, in vivo model validation, and in vitro and in vivo pharmacological and pharmacodynamic evaluation.





Ding Duanchen, PhD

### CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS

Duanchen Ding received his undergraduate degree from Peking University, then went to the United States to study and re ceived his PhD from Purdue University under the supervision of Prof Hikka I. Kenttamaa, AAAS Fellow and 2015 ACS Na tional Award Winner.

In order to accelerate the process of new drug development and to provide a more effective evaluation platform, Dr. Ding has led the team to develop the construction of complex tumour-related models, and has completed the construction of tu mour immunity and super-mimetic tumour organoid models based on the organoid microarrays, evaluated the efficacy of anti-tumour small and large molecules, nucleic acid drugs, cellular drugs, and tumour immunity-related drugs, and has hel ped our partners in completing the IND filing of the new drugs.

At the same time, the team uses primary cells, physiological organoids and other highly bionic in vitro models to carry out drug high-throughput screening, pharmacodynamic evaluation and translational medicine research, involving drug ADME T evaluation, special disease model construction and the corresponding efficacy evaluation. We provide more innovative and bionic evaluation tools for new drug development.





Huafang Jiang, PhD

#### **CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS**

PhD in Pharmaceutical Analysis.

Former director of bioanalysis department at WuXi. 20+ years of experience on bioanalysis to support pr eclinical, TOX, Clinical PK&PD, biomarker etc, including 12+ GxP bioanalysis.

Established an in-vitro and in-vivo bioanalysis team supporting drug research and development in WuXi's DMPK department. Supported thousands of drugs screening and evaluation in vitro and in-vivo assays, such as rodent PK, in vitro permeability, in vitro metabolic stability, DDI tests, etc. Participated in 100+ a udits of clients and regulatory such as NMPA, FDA, OECD, EMA and MHLW, etc. Completed 50+ GCLP me thod development, validation and sample analysis, supporting preclinical TOX, BE, clinical phase I\II\III for NMPA and FDA submission. Participated in the translation of <code>%handbook</code> of LC-MS Bioanalysis-Best Practice Experimental Protocols, and Regulations.

Gave speeches on academic forums and live classes such as "The bioanalysis strategy of small molecular biomarkers", "The application of protein biomarkers in pharmaceutical R&D and bioanalysis strategy", "The application of Bio-Plex in Gene Therapy", "The bioanalysis strategy and challenges of antibody—drug conjugates", etc.





Qi Huang, PhD

#### CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS

#### Deputy Director in the Preclinical Development at Simcere Zaiming in Shanghai

As a project leader, Qi supports preclinical development and is responsible for nonclinical toxicology and pharmacokinetic studies of oncology drug programs. He holds PhD in Pharmacology from the Chinese Aca demy of Sciences where his research focused on metabolic disease.

Qi began his career at Wuxi AppTec as a project leader of in vitro discovery biology. Prior to joining Simcer e Zaiming, he was an Assistant Director in the Preclinical Development at Hengrui in Shanghai. After almo st 8 years in industry, Qi has managed nonclinical toxicology and pharmacokinetic studies of more than 20 new drug programs, among which 4 products have been approved for marketing.





Won-seok Nam(Ph.D)

#### **CAREER EXPERIENCES/PROFESSIONAL POSITIONS AND EMPLOYMENTS**

Former Senior Researcher/Part Manager, Non-clinical PK, Xenia Materials Analysis Team

Former Head of Analytical Team 1, Phase I Biospecimen Analysis Team, Department of Pharmacol ogy, Seoul National University College of Medicine